A new cannabis vaping device is set to help consumers find the right dose for them.
Thought to be the world’s first, a new smart cannabis dosing device in the US will allow consumers to measure their dosage more accurately.
Its founders say Mode provides a sensible approach to consumption by removing the guesswork out of dosing and helping consumers achieve the ideal experience every time.
The device’s touch slider function allows users to adjust their dose with precision down to the milligram, while the haptic guidance feature lets users know exactly when to stop inhaling and when to exhale, with a gentle vibration from the device.
Mode can be locked manually or remotely with the companion app, which also features a control dashboard for personalised cannabis consumption, with access to detailed dosage plans, product information, feedback loop, personalised recommendations and consumption analytics.
Founded by cannabis visionaries Izzy Kirsh, Mark (Akiva) Wagner and Stephen Bates, the Mode platform was designed for wellness and recreational users alike.
The idea was realised after Kirsh suffered a personal injury, which led him to identify the opportunity and need for personalised and sensible cannabis dosing.
The trio then collaborated with a world-class design and engineering team and raised $2.5million in funding to bring Mode to the US market.
“At Mode, we are about elevating cannabis from an escape or just ‘a good time’ into a powerful tool for health and wellness,” said Stephen Bates, co-founder and director of product.
“Whether it’s to relieve pain, spark creativity, or lull you to sleep, we offer a ‘mode’ for your unique needs and endocannabinoid system.”
Coming from years in the black market, cannabis is missing a set of guidelines and structure to achieve specific health and wellness objectives for mainstream consumers.
With over 100 cannabinoids and terpenes in the cannabis plant, the industry is just scratching the surface of the science behind cannabis and how specific cannabinoids can provide targeted medicinal and therapeutic results.
“We initially set out to solve the dosing dilemma for people requiring cannabis to treat injuries, ailments and other health-related matters,” said Izzy Kirsh, co-founder and co-CEO.
“We built dozens of prototypes to deliver vapor doses by the milligram, perfecting consumption levels down to a rudimentary science of what cannabinoids and dosages are required to achieve the right results.
“What we ultimately created is a first-of its-kind device that offers more control and a better experience for all cannabis consumers.”
Mark (Akiva) Wagner co-founder and co-CEO added: “Cannabis is a dosage-sensitive substance and not a one-size-fits-all solution.
“Mode offers a missing device and dataset for the cannabis space, and with the correct analysis and implementation, can open pathways of understanding never seen before in cannabis.”
Mode is available for preorder in the US and will retail for $100 when it’s available later this year.
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure